Adeno-associated virus as a delivery vector for gene therapy of human diseases
Аденоассоциированный вирус как вектор доставки для генной терапии заболеваний человека
2024-04-02
SCID: 54.1/6ahxsc7e
Discuss with AI
Adeno-associated virusgene therapyimmune responsesrecombinant AAVvector engineering
Figures from the paper
Abstract (AI)
Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene therapy owing to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. Recombinant AAV (rAAV) has been engineered for enhanced specificity and developed as a tool for treating various diseases. However, as rAAV is being more widely used as a therapy, the increased demand has created challenges for the existing manufacturing methods. Seven rAAV-based gene therapy products have received regulatory approval, but there continue to be concerns about safely using high-dose viral therapies in humans, including immune responses and adverse effects such as genotoxicity, hepatotoxicity, thrombotic microangiopathy, and neurotoxicity. In this review, we explore AAV biology with an emphasis on current vector engineering strategies and manufacturing technologies. We discuss how rAAVs are being employed in ongoing clinical trials for ocular, neurological, metabolic, hematological, neuromuscular, and cardiovascular diseases as well as cancers. We outline immune responses triggered by rAAV, address associated side effects, and discuss strategies to mitigate these reactions. We hope that discussing recent advancements and current challenges in the field will be a helpful guide for researchers and clinicians navigating the ever-evolving landscape of rAAV-based gene therapy.
Key Findings
1
AAV has become a pivotal gene-delivery vector because of minimal pathogenicity and sustained gene expression across diverse tissues.
2
Growing rAAV use has exposed manufacturing challenges caused by increased demand and the complexity of producing therapeutic vectors.
3
High-dose rAAV therapies raise safety concerns, including immune responses, genotoxicity, hepatotoxicity, thrombotic microangiopathy, and neurotoxicity.
4
Immune-response mitigation strategies are needed to improve the safety of rAAV-based gene therapies.
5
Recombinant AAV engineering improves delivery specificity and supports therapeutic development for ocular, neurological, metabolic, hematological, neuromuscular, cardiovascular diseases, and cancers.
6
Seven rAAV-based gene therapy products have received regulatory approval, demonstrating clinical translation of the platform.
Research Object
Recombinant adeno-associated virus (rAAV) vectors for gene therapy
Research Subject
vector engineering, manufacturing, clinical applications, immune responses, and safety challenges of rAAV-based gene therapy
Publication Details
Publication Date
2024-04-02
Journal
Publisher
ISSN
Cited by
832
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest